The role of preclinical animal models in breast cancer drug development

[1] Polychemotherapy for early breast cancer: an overview of randomised trials, Lancet, 352, pp. 930-942, (1998)

[2] Fisher B., Dignam J., Mamounas E.P., Costantino J.P., Wickerham D.L., Redmond C., Wolmark N., Dimitrov N.V., Bowman D.M., Glass A.G., Atkins J.L., Abramson N., Sutherland C.M., Aron B.S., Margolese R.G., Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate

[3] Mansour E.G., Gray R., Shatila A.H., Tormey D.C., Cooper M.R., Osborne C.K., Falkson G., Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis - an intergroup study, J Clin Oncol, 16, pp. 3486-3492, (1998)

[4] Tamoxifen for early breast cancer: an overview of the randomized trials, Lancet, 351, pp. 1451-1467, (1998)

[5] Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet, 399, pp. 1-15, (1992)

[6] Rosen P.R., Groshen S., Saigo P.E., Kinne D.W., Hellman S., A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma, J Clin Oncol, 7, pp. 355-366, (1989)

[7] Hellman S., Harris J.R., Natural history of breast cancer, Disease of the Breast, pp. 407-423, (2000)

[8] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, 2008, CA Cancer J Clin, 58, pp. 71-96, (2008)

[9] Zhang Y., Soumerai S.B., Do newer prescription drugs pay for themselves? A reassessment of the evidence, Health Aff (Millwood), 26, pp. 880-886, (2007)

[10] Baker D., Fugh-Berman A., Do new drugs increase life expectancy? A critique of a Manhattan institute paper, J Gen Intern Med, 24, pp. 678-682, (2009)

[1] Polychemotherapy for early breast cancer: an overview of randomised trials, Lancet, 352, pp. 930-942, (1998)

[2] Fisher B., Dignam J., Mamounas E.P., Costantino J.P., Wickerham D.L., Redmond C., Wolmark N., Dimitrov N.V., Bowman D.M., Glass A.G., Atkins J.L., Abramson N., Sutherland C.M., Aron B.S., Margolese R.G., Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate

[3] Mansour E.G., Gray R., Shatila A.H., Tormey D.C., Cooper M.R., Osborne C.K., Falkson G., Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis - an intergroup study, J Clin Oncol, 16, pp. 3486-3492, (1998)

[4] Tamoxifen for early breast cancer: an overview of the randomized trials, Lancet, 351, pp. 1451-1467, (1998)

[5] Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet, 399, pp. 1-15, (1992)

[6] Rosen P.R., Groshen S., Saigo P.E., Kinne D.W., Hellman S., A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma, J Clin Oncol, 7, pp. 355-366, (1989)

[7] Hellman S., Harris J.R., Natural history of breast cancer, Disease of the Breast, pp. 407-423, (2000)

[8] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, 2008, CA Cancer J Clin, 58, pp. 71-96, (2008)

[9] Zhang Y., Soumerai S.B., Do newer prescription drugs pay for themselves? A reassessment of the evidence, Health Aff (Millwood), 26, pp. 880-886, (2007)

[10] Baker D., Fugh-Berman A., Do new drugs increase life expectancy? A critique of a Manhattan institute paper, J Gen Intern Med, 24, pp. 678-682, (2009)